In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzon Pharmaceuticals, Inc.

http://enzon.com/

Latest From Enzon Pharmaceuticals, Inc.

Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis

Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.

Deals Business Strategies

Mabxience Allies With Zentiva For European Bevacizumab Launch

Mabxience and Zentiva have partnered to launch the Alymsys bevacizumab biosimilar rival to Avastin that recently received a pan-European marketing authorization.

Biosimilars Launches

Zentiva's Zent2U Claims Advantage On EU Entresto Entry

Zentiva’s Zent2U B2B unit says that it will be ready to register for a European generic version of Novartis’ Entresto immediately upon data exclusivity expiry, putting its version in position for a “day one” launch once intellectual property protecting the cardiovascular blockbuster expires.

Generic Drugs Intellectual Property

AbiVax Poised For 'Transformational' Q2

Q2 promises to be ‘transformational’ for AbiVax, propelled by key readouts for investigational anti-inflammatory, ABX464, and cancer agent, ABX196, but more funds will be needed by year end.

Clinical Trials Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
UsernamePublicRestriction

Register